08.04.24 | Vollzeit | Dachau | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Dachau | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | München | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Dachau | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Königsbrunn | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Fürstenfeldbruck | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | München | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Germering | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Power Company in Dachau Landkreis kostenlos abonnieren.